Advancing Genetically Validated Targets & Combination Development Strategies to Improve Therapeutic Precision, Enable Differentiation & Support Long-Term Success in MASH
- Leveraging insights from genetically validated disease drivers to identify high confidence therapeutic targets, enabling more informed development strategies and improving the likelihood of clinical success
- Evaluating how emerging targets associated with metabolic dysfunction and fibrotic progression may complement existing therapeutic approaches, strengthening differentiation opportunities and expanding future treatment potential
- Exploring how genetically informed therapies could be incorporated into combination development strategies to address multiple disease drivers simultaneously, enabling broader therapeutic impact and improving long-term patient outcomes